文献速递骨软组织肉瘤与黑色素瘤

p53 药理激活触发病毒模拟反应从而消除肿瘤免疫逃逸并促进抗肿瘤免疫

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity.
PubMed 文献 · Cancer Discov · 2021-01-01

研究发现 MDM2 抑制剂激活的 p53 通过增加 ERV 启动子占据并抑制 LSD1 和 DNMT1 诱导内源性逆转录病毒表达,产生的双链 RNA 应激触发 I/III 型干扰素表达及抗原加工提呈。体内 p53 激活释放干扰素程序、促进 T 细胞浸润并显著增强同种移植瘤模型中检查点治疗疗效,MDM2 抑制剂 ALRN-6924 在黑色素瘤患者中诱导病毒模拟通路和肿瘤炎症特征基因。

要点

  • MDM2 抑制剂激活 p53 通过抑制 LSD1 和 DNMT1 诱导 ERV 表达。
  • ERV 来源双链 RNA 触发 I/III 型干扰素表达和抗原提呈。
  • p53 激活增强检查点治疗疗效,ALRN-6924 在黑色素瘤患者诱导病毒模拟通路。

核心结论

  • p53 激活通过诱导 ERV 表达克服肿瘤免疫逃逸并将肿瘤微环境转变为有利表型。
  • MDM2 抑制剂与免疫治疗联用具有协同作用的机制依据。

研究设计与样本

  • 研究采用体外与体内实验,并在同种移植瘤模型中验证 p53 激活对检查点治疗的影响。
  • 在黑色素瘤患者中评估 MDM2 抑制剂 ALRN-6924 对病毒模拟通路和肿瘤炎症特征基因的诱导。

主要发现

  • MDM2 抑制剂激活的 p53 通过增加 ERV 启动子占据并抑制 LSD1 和 DNMT1 诱导 ERV 表达。
  • ERV 引起的双链 RNA 应激触发 I/III 型干扰素表达及抗原加工和提呈。
  • 体内 p53 激活释放干扰素程序、促进 T 细胞浸润并显著增强同种移植瘤模型中检查点治疗疗效。
  • ALRN-6924 在黑色素瘤患者中诱导病毒模拟通路和肿瘤炎症特征基因。

临床怎么用

  • MDM2 抑制剂激活 p53 可诱导病毒模拟和干扰素反应,为联合免疫检查点治疗提供依据。
  • 该机制可能将「冷」肿瘤转变为「热」肿瘤,克服免疫检查点阻断耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The repression of repetitive elements is an important facet of p53's function as a guardian of the genome. Paradoxically, we found that p53 activated by MDM2 inhibitors induced the expression of endogenous retroviruses (ERV) via increased occupancy on ERV promoters and inhibition of two major ERV repressors, histone demethylase LSD1 and DNA methyltransferase DNMT1. Double-stranded RNA stress caused by ERVs triggered type I/III interferon expression and antigen processing and presentation. Pharmacologic activation of p53 in vivo unleashed the IFN program, promoted T-cell infiltration, and significantly enhanced the efficacy of checkpoint therapy in an allograft tumor model. Furthermore, the MDM2 inhibitor ALRN-6924 induced a viral mimicry pathway and tumor inflammation signature genes in patients with melanoma. Our results identify ERV expression as the central mechanism whereby p53 induction overcomes tumor immune evasion and transforms tumor microenvironment to a favorable phenotype, providing a rationale for the synergy of MDM2 inhibitors and immunotherapy. SIGNIFICANCE: We found that p53 activated by MDM2 inhibitors induced the expression of ERVs, in part via epigenetic factors LSD1 and DNMT1. Induction of IFN response caused by ERV derepression upon p53-targeting therapies provides a possibility to overcome resistance to immune checkpoint blockade and potentially transform "cold" tumors into "hot." This article is highlighted in the In This Issue feature, p. 2945.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhou X, Singh M, Sanz Santos G, et al. Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity. Cancer Discov. 2021. PMID: 34230007. doi:10.1158/2159-8290.CD-20-1741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。